Retinitis Pigmentosa: FDA approves first retinal implant for advanced adult RP

ByConnor Hodde

Retinitis pigmentosa (RP) is a group of inherited disorders characterized by progressive peripheral vision loss and night vision difficulties (nyctalopia) that can lead to central vision loss. The US Food and Drug Administration (FDA) has approved the first retinal implant, the Argus II Retinal Prosthesis System, for adults aged 25 years or older with advanced RP. The implant includes a small video camera, transmitter mounted on a pair of eyeglasses, video processing unit (VPU), and an implanted retinal prosthesis (artificial retina). The VPU transforms images from the video camera into electronic data that are wirelessly transmitted to the retinal prosthesis.

Read the entire article here

Similar Posts

Curing blindness by repairing corneas with invisible films

ByConnor Hodde

The University of Melbourne–lead team of researchers have grown corneal cells on a layer of film that can be implanted in the eye to help the cornea heal itself. They have successfully restored vision in animal trials and are aiming to move to human trials next year.  “The hydrogel film we have developed allows us to…

Partnership Aims to Take Advantage of Preclinical Ophthalmology Developments

ByConnor Hodde

Rafal Farjo, PhD, COO of eyecro, told Outsourcing-pharma.com that the “demand for ophthalmology studies is increasing.  Many research scientists are uncovering new mechanisms and targets for ophthalmic disease, it is also becoming apparent that there is pathology in common with many other clinical indications.   eyecro specializes in ophthalmic studies of preclinical efficacy, pharmacokinetics, toxicology, and…

Pharma News: Bayer, Johns Hopkins partner to develop new ophthalmic therapies

ByConnor Hodde

Bayer HealthCare has entered into a five-year collaboration agreement with The Johns Hopkins University in Baltimore, US, for the discovery and development of new therapies in ophthalmology targeting retinal diseases.  Both the parties will jointly conduct research activities evaluating new targets and disease mechanisms, drug delivery technologies, and biomarkers for back-of-the-eye diseases with high unmet…

Amarantus Announces the Presentation of Data Showing MANF”s Positive Effect on Retinal Function at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

ByConnor Hodde

Amarantus BioScience Holdings, Inc. announced the presentation of positive preclinical data for MANF (mesencephalic-astrocyte-derived neurotrophic factor) in retinitis pigmentosa (RP) at the Association for Research in Vision and Ophthalmology Annual Meeting, being held in Denver, CO. The results from preclinical studies demonstrate that MANF preserves the light-sensing function of photoreceptor cells in a genetic model of…

EyeCRO and MPI Research Partner to Develop New Preclinical Models of Ophthalmic Disease

ByConnor Hodde

Oklahoma City, OK; Ann Arbor, MI; and Mattawan, MI (PRWEB) May 01, 2017 eyecro and MPI Research, two global leaders in preclinical ophthalmology contract research, today announced a collaboration to develop and commercialize large mammalian preclinical models for various ophthalmic diseases, including Age-Related Macular Degeneration and Diabetic Retinopathy. The partnership leverages the unique skills and…

New Trial Shows Drugs are Effective for Diabetic Macular Edema

ByConnor Hodde

 Diabetes is a significant risk factor for developing eye diseases. The most common diabetic eye disease and a leading cause of blindness is diabetic retinopathy.  Americans with diabetic retinopathy have diabetic macular edema (DME) in which fluid leaks into the macula, the area of the retina used when looking straight ahead.  Over the past few…